

International Congress of Breast Disease Centers 201

QUALITY AND INNOVATION IN BREAST CENTERS

PARIS (France) - February 4 - 6, 2016

Venue: Espace Morin, 14 rue du Vertbois, 75003 Paris

ABRCAdaBRA: Opening the Way to Women with a BRCA Mutation in Italy





Ornella Campanella February 5, 2016





Everythings was born on Facebook two years ago.

Then we met in Pavia during the 4° Pavia Update on Breast Cancer in May 2014 Women shared experiences, critical issues on italian management of High risk patients

Today we have 380 members, mostly women and few men

From the virtual world, we moved into the real one, supported by Europa Donna since the beginning

4TH PAVIA UPDATE ON BREAST CANCER

Rischio eredo-familiare di carcinoma mammario e ovarico: dalle evidenze scientifiche alla applicazione sul territorio nazionale



4TH PAVIA UPDATE ON BREAST CANCER





Italy do not have BRCA advocacy activity

So this is why we feel the need to create a dedicate women (and man) Association

- 1) To give voice to the needs of HIGH risk Women BRCA carriers
- 2) Working together with Health care specialists to have well defined NATIONAL GUIDELINES on Management of this high risk population ensuring the proper surveillance protocol and the appropriate management in all regions
- 3) Support the need of implement BREAST UNITS following European Criteria with a Muldisciplinary approach and Clinical experts (breast surgeon, oncologist, Nurse/case manager, psycologist, gynecologist, geneticist, plastic surgeon, radiologist, radiotherapist
- 4) Promote a National BRCA registry (to have more data about this population)

Many studies demonstrate how is important in terms of mortality, that a woman is followed in Breast Unit compare to a surgical ward.





DIPARTIMENTO DELLA PROGRAMMAZIONE E

DELL'ORDINAMENTO DEL SSN

DIREZIONE GENERALE DELLA PROGRAMMAZIONE

EX UFFICIO III DG PROG

Documento del Gruppo di lavoro per la definizione di specifiche modalità organizzative ed assistenziali della rete dei centri di senologia

D.M. 27 MAGGIO 2014

Why a registry?

We all know that about 5-10% of breast cancers can be linked to gene mutations inherited from one's mother or father. Mutations of the BRCA1 and BRCA2 genes are the most common. On average, women with a BRCA1 mutation have a 55-65% lifetime risk of developing breast cancer. For women with a BRCA2 mutation, the risk is 45%. Breast cancer that is positive for the BRCA1 or BRCA2 mutations tends to develop more often in younger women. An increased ovarian cancer risk is also associated with these genetic mutations. In men, BRCA2 mutations are associated with a lifetime breast cancer risk of about 6.8%; BRCA1 mutations are a less frequent cause of breast cancer in men

What about Italy?

Who knows how many we are?

When we do the genetic test?

If we develop breast or ovarian cancer, what about the age?

Are we young?

What about the biology of the tumor? (Triple negative, Hormone sensitive, HER-2, Ki 67 high or low?

Are there regions able to intercept those carriers **BEFORE** they develop cancer?

How many women have choosen prophylactic surgery compare to surveillance? And what happen after?

Did they survive more?



How many Hospitals/centers are able to perform BRCA test?



2015

BREAST UNIT IN ITALIA DOVE È POSSIBILE EFFETTUARE IL TEST GENETICO PER MUTAZIONE BRCA



5) Provide free diagnostic and laboratory tests for BRCA carrier (D99) in all Italian Regions (not just two)

NOVITÀ ESENZIONI: DELIBERA DELLA REGIONE LOMBARDIA X/3993 DEL 04/08/2015

21/08/2015

ESENZIONE DALLA COMPARTECIPAZIONE ALLA SPESA SANITARIA PER ALCUNI SOGGETTI PORTATORI DI MUTAZIONI GENETICHE CHE CONFERISCONO UN ALTO RISCHIO DI SVILUPPO DI TUMORI E NECESSITANO PERTANTO DI UNA SORVEGLIANZA INTENSIVA: si prevede un nuovo codice di esenzione D99 per le prestazioni specialistiche correlate alla diagnosi precoce del tumore della mammella e dell'ovaio in pazienti con riscontro di rischio eredo – familiare. La nuova esenzione D99 entrerà in vigore dopo 45 giorni dall'adozione dell'atto in oggetto (16 settembre 2015)

Population-Based Screening for BRCA1 and BRCA2

To identify a woman as a carrier only *after* she develops cancer is a failure of cancer prevention.



Mary-Claire King, PhD Departments of Medicine and Genome Sciences, University of Washington, Seattle.

Knowledge is power








I have to say....
Thank you
Angelina

In those days, we heard the worst opinions!!

By journalist, entertainers, actors, even surgeons and famous oncologists during interviews and talk shows providing personal opinions.

Like in a ring. And always without women This is why aBRCAdaBRA







stropo asci asconiasses, ha detto la Jolic, sterò questa nuova fasses, ha detto la Jolic, nuovo intervento ammurciato. Il motivo? trice ripete, com ammurciato. Il motivo? trice ripete, com ci perdermis. C'è sicurade del pevo. Ed è possibile che questa sia decisione lucida, bassita su un preciso calsdelle possibilità. Non si può non pensaperò, che questi interventi siano l'estre-espressione del rapporto tormentato Angelina ha con il suo corpo, inciso dai aggi e a volte così magro da far sospete disturbi alimentari. Del resto, in una insista, la Jolie aveva confessato come, prima ssere madre, si tagliasse gambe e brac-



One year ago and today....











We need to feel respect, kindness, courtesy and competency.

Invite women to do their surveillance without using women body as a tool to think always about sex.

And finally we have the Association







CHI SIAMO

ASSOCIATI

CONTATTI


www.abrcadabra.it

An initial study inside the group




- ► Group Brca1-Brca2 composed by 350 people
- ► Test completed 90
- Data needs to be considered as initials
- Mean: Woman 42 years old, married, one child

Brest cancer already presented in your family?



Ovarian cancer already presented in your family?



How many case of tumors in your family?

Breast

Ovarian


from1 to more then 3 cases

from 1 to more then 3 cases


92%

46 %


Where you did or will do the test?




Access to the test. It was easy??



HOW DID YOU KNOW ABOUT THE TEST?




When you did the test?




Are you positive for...?







IN YOUR OPINION, COULD YOU BE INFORMED ABOUT THE TEST IN ADVANCE?




How many years in advance?



If done in advance, do you think someone of your family could prevent the disease?



Did you already develop breast or ovarian cancer?



Tumor Biology

- ▶ 50% TRIPLE NEGATIVE
- **27%** Her-
- > 23% Her+

- 13 women already had Breast cancer recurrence
- 4 women had breast cancer for the third time
- 14 women had disease progression (locally, metastasis or stage IV)

Women age

Prophylactic group

Breast 36 years

Ovarian 39,5 years

Disease group (First tumor)

Breast 39 years

Ovarian 57 years

After the test: healthy women

- > 40% chose or will choose prophylactic mastectomy
- > 30% chose surveillance

13% already underwent prophylactic oophorectomy to reduce breast cancer

4% will do surveillance without any surgeries

For ovarian

- > 53% did oophorectomy)
- 39 % is following surveillance, will do surgery later
- 4% is following surveillance but will not have any surgery
- 4% did not decide yet

First steps

First Working group
March 2015:
To meet









Donne Italiane con Mutazione Genetica BRCA: primo incontro

https://www.youtube.com/watch?v=H107quY11sk

What happened in the last months?

NOVITÀ ESENZIONI: DELIBERA DELLA REGIONE LOMBARDIA X/3993 DEL 04/08/2015

21/08/2015

ESENZIONE DALLA COMPARTECIPAZIONE ALLA SPESA SANITARIA PER ALCUNI SOGGETTI PORTATORI DI MUTAZIONI GENETICHE CHE CONFERISCONO UN ALTO RISCHIO DI SVILUPPO DI TUMORI E NECESSITANO PERTANTO DI UNA SORVEGLIANZA INTENSIVA: si prevede un nuovo codice di esenzione D99 per le prestazioni specialistiche correlate alla diagnosi precoce del tumore della mammella e dell'ovaio in pazienti con riscontro di rischio eredo – familiare. La nuova esenzione D99 entrerà in vigore dopo 45 giorni dall'adozione dell'atto in oggetto (16 settembre 2015).











Invited as Faculty
Ottobre 2015



CONTROVERSIE DELLA MASTECTOMIA PROFILATTICA





LAST Two months

Second Working group 28 Novembre 2015





II Incontro di Lavoro aBRCAdaBRA & EDI

"Donne a rischio genetico di tumore al seno e all'ovaio"

Presidente: Alberta Ferrari

Segreteria Scientifica: Ornella Campanella, Fabiana Gregori, Rita Nonnis

Pavia
28 novembre 2015
Fondazione IRCC\$ Policlinico \$an Matteo





We spoke about:

- Maternity and BRCA (7 testimonials)
- Costs of surveillance in Italy
- Caracteristic of Women with BRCA mutation in the group
- The website
- Meet people, increase culture of prevention





QUALITY AND INNOVATION IN BREAST CENTERS

PARIS (France) - February 4 - 6, 2016

Next steps







The e-book Women are told

This is why the need of a National Association



To represent who is not able to say ... Please help me.. I'm not able to speak about my disease and my family loss

«With you, I'm not lonely... anymore»



